搜索
 >  其他蛋白>Cetuximab >CEB-Y28

Anti-Cetuximab Antibodies

表达区间及表达系统(Source)

Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2.

亚型(Isotype)

IgG1/kappa

特异性(Specificity)

Recognizes Cetuximab specifically, no cross reactivity with other humanized antibodies.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 3 years under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) SDS-PAGE gel

Anti-Cetuximab Antibodies on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Anti-Cetuximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized cetuximab at 1 µg/mL, add increasing concentrations of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28, 10% human serum) and then add biotinylated cetuximab at 5 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 2.4 ng/mL.

Protocol

Biotinylated Human SPR

Demonstration of the specificity of Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) to the cetuximab.

Protocol

Biotinylated Human ELISA

Measured by its neutralizing ability in a functional ELISA. Immobilized cetuximab at 0.2 μg/mL (100 μL/well) can bind pre-mixed Anti-Cetuximab Antibodies (Cat. No. CEB-Y28) and Biotinylated EGFRvIII (Cat. No. EGR-H82E0) with an inhibition rate of 100%.

Protocol

活性(Bioactivity)-SPR

Biotinylated Human SPR

Anti-Cetuximab Antibodies (mouse IgG1, Cat. No. CEB-Y28) captured on CM5 chip via anti-mouse antibodies surface, can bind Human cetuximab with an affinity constant of 1.51 pM.

Protocol

 

背景(Background)

Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

 

前沿进展

 
 
货号/价格
开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定